- Home
- QNRX vs NCNA Comparison
QNRX vs NCNA Comparison
Compare QNRX & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNRX
- NCNA
- Stock Information
- Founded
- QNRX 2018
- NCNA 1997
- Country
- QNRX United States
- NCNA United Kingdom
- Employees
- QNRX 3
- NCNA N/A
- Industry
- QNRX Medical/Dental Instruments
- NCNA Biotechnology: Pharmaceutical Preparations
- Sector
- QNRX Health Care
- NCNA Health Care
- Exchange
- QNRX Nasdaq
- NCNA Nasdaq
- Market Cap
- QNRX 4.0M
- NCNA 4.5M
- IPO Year
- QNRX N/A
- NCNA 2017
- Fundamental
- Price
- QNRX $6.97
- NCNA $0.04
- Analyst Decision
- QNRX
- NCNA Buy
- Analyst Count
- QNRX 0
- NCNA 2
- Target Price
- QNRX N/A
- NCNA $25.00
- AVG Volume (30 Days)
- QNRX 4.1K
- NCNA 298.8M
- Earning Date
- QNRX 08-07-2025
- NCNA 08-14-2025
- Dividend Yield
- QNRX N/A
- NCNA N/A
- EPS Growth
- QNRX N/A
- NCNA N/A
- EPS
- QNRX N/A
- NCNA N/A
- Revenue
- QNRX N/A
- NCNA N/A
- Revenue This Year
- QNRX N/A
- NCNA N/A
- Revenue Next Year
- QNRX N/A
- NCNA N/A
- P/E Ratio
- QNRX N/A
- NCNA N/A
- Revenue Growth
- QNRX N/A
- NCNA N/A
- 52 Week Low
- QNRX $5.01
- NCNA $0.03
- 52 Week High
- QNRX $54.95
- NCNA $10.79
- Technical
- Relative Strength Index (RSI)
- QNRX 26.23
- NCNA 39.72
- Support Level
- QNRX $6.67
- NCNA $0.04
- Resistance Level
- QNRX $8.69
- NCNA $0.07
- Average True Range (ATR)
- QNRX 0.34
- NCNA 0.01
- MACD
- QNRX -0.22
- NCNA 0.00
- Stochastic Oscillator
- QNRX 1.08
- NCNA 30.00
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.